A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

PHASE3CompletedINTERVENTIONAL

Enrollment

319

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

October 25, 2023

Study Completion Date

May 9, 2024

Conditions

Type 2 Diabetes

Interventions

OTHER

placebo

placebo administered subcutaneously (SC) once a week.

DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

Trial Locations (1)

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY